Mexico’s antitrust commission opened an investigation into possible monopolistic practices in the medicines sector, which has been under scrutiny since a leak earlier this year from the Panama papers revealed a questioned deal involving the country’s largest private drug distributor.
In a statement Wednesday, the federal competition commission said “some public information” prompted the investigation, which was opened in May. The commission can initiate probes before making them public to determine whether there are grounds for continuing the investigation.
The commission said it is investigating possible monopolist practices, such as price-fixing or allocation of customers between market players, in the production, distribution and sale of medicines in Mexico.
The commission said the investigation includes the purchase of the country’s third-largest pharmaceutical distributor, Casa Marzam SA, by a little-known Dutch fund, since the companies involved are part of the distribution chain, although the overall investigation is much broader.
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletterr for more headlines and updates on antitrust developments around the world.
Featured News
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Spanish Startup Association Slams Microsoft’s Cloud Practices
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI